Overview

Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Primary Sjögren syndrome is one of the most prevalent autoimmune diseases that present with dry eye and dry mouth. But there is no proven effective treatment for Sjögren syndrome patient. The relation between toll-like receptor (TLR) and the pathogenesis of Sjögren syndrome has been reported. Hydroxychloroquine is TLR7 and TLR9 antagonist. A few studies have been reported the effectiveness of Hydroxychloroquine for Sjögren syndrome but no randomized controlled study has been done. So the investigators evaluate the effectiveness and safeness of Hydroxychloroquine for primary Sjögren syndrome by randomized controlled study (Hydroxychloroquine 300 mg once daily p.o. group (N = 30) versus placebo group (N = 30).
Phase:
Phase 3
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Hydroxychloroquine